Revolution Medicines (RVMD) Stock Forecast & Price Target

$47.32

+1.19 (+2.58%)

(As of 10/4/2024 ET)

Revolution Medicines - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
0

Buy
11

Based on 11 Wall Street analysts who have issued ratings for Revolution Medicines in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 10 have given a buy rating, and 1 has given a strong buy rating for RVMD.

Consensus Price Target

$54.00
14.12% Upside

According to the 11 analysts' twelve-month price targets for Revolution Medicines, the average price target is $54.00. The highest price target for RVMD is $63.00, while the lowest price target for RVMD is $40.00. The average price target represents a forecasted upside of 14.12% from the current price of $47.32.

Get the Latest News and Ratings for RVMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Revolution Medicines and its competitors.

RVMD Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$54.00	$52.92	$45.00	$35.57
Forecasted Upside	14.12% Upside	26.47% Upside	13.69% Upside	42.06% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Next opportunity for crypto millions (Ad)

The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine…

Go here to discover the crypto that's about to leave Wall Street in the dust.

RVMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RVMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Revolution Medicines Stock vs. The Competition

Type	Revolution Medicines	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	14.12% Upside	10,592.03% Upside	7.02% Upside
News Sentiment Rating	Positive News See Recent RVMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/27/2024	Barclays 3 of 5 stars	P. Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$54.00 ➝ $60.00	+34.80%
8/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$56.00 ➝ $56.00	+30.54%
8/8/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$55.00 ➝ $54.00	+27.30%
8/8/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$59.00 ➝ $59.00	+40.28%
8/8/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$62.00 ➝ $61.00	+44.31%
7/16/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$45.00 ➝ $55.00	+19.57%
Get the Latest News and Ratings for RVMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.
7/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$48.00 ➝ $55.00	+19.57%
7/8/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$63.00	+67.87%
4/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Outperform ➝ Strong-Buy	$36.00 ➝ $48.00	+45.50%
3/11/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$43.00	+33.33%
12/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+46.84%
9/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$37.00 ➝ $47.00	+58.09%
3/1/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$20.00 ➝ $23.00	-13.60%
2/28/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$38.00	+38.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:30 AM ET.

RVMD Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Revolution Medicines is $54.00, with a high forecast of $63.00 and a low forecast of $40.00.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares.
: According to analysts, Revolution Medicines's stock has a predicted upside of 14.12% based on their 12-month stock forecasts.
: Revolution Medicines has been rated by research analysts at Bank of America, Barclays, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, and Wedbush in the past 90 days.
: Analysts like Revolution Medicines more than other "medical" companies. The consensus rating for Revolution Medicines is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RVMD compares to other companies.